Recent News

• 06.08.2026 - Mineralys Therapeutics to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference
• 06.08.2026 - Mineralys Therapeutics to Present Late-Breaking Data on Lorundrostat at The Endocrine Society Annual Meeting (ENDO 2026)
• 06.03.2026 - Mineralys Therapeutics Announces Pricing of $150 Million Underwritten Offering of Common Stock
• 06.03.2026 - Mineralys Therapeutics Announces Repurchase of Royalty Obligations in Tanabe License Agreement and Concurrent Financing
• 05.30.2026 - Mineralys Therapeutics Presents New Data from the Phase 3 Launch-HTN Trial of Lorundrostat in Participants with Hypertension and Chronic Kidney Disease at European Meeting on Hypertension and Cardiovascular Protection (ESH 2026)
• 05.27.2026 - Mineralys Therapeutics to Participate in the Jefferies Global Healthcare Conference
• 05.18.2026 - Mineralys Therapeutics Announces Presentation of New Data from the Phase 3 Launch-HTN Trial of Lorundrostat at the 35th European Meeting on Hypertension and Cardiovascular Protection (ESH 2026)
• 05.06.2026 - Mineralys Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

Recent Filings

• 06.10.2026 - 144 Report of proposed sale of securities
• 06.03.2026 - 8-K Current report
• 06.03.2026 - EX-99.1 EX-99.1
• 06.03.2026 - 424B5 Prospectus [Rule 424(b)(5)]
• 06.03.2026 - 8-K Current report
• 05.22.2026 - 8-K Current report
• 05.19.2026 - 4 Statement of changes in beneficial ownership of securities
• 05.18.2026 - 144 Report of proposed sale of securities
• 05.13.2026 - 144 Report of proposed sale of securities
• 05.13.2026 - 4 Statement of changes in beneficial ownership of securities